Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Acta Pharmaceutica Sinica ; (12): 1544-1549, 2013.
Artigo em Chinês | WPRIM | ID: wpr-298046

RESUMO

Anti-angiogenesis mechanism plays a vital role in tumor targeting immunotherapy. Based on the amino acid sequence of an anti-VEGFR-2 scFv-Fc fusion antibody (AK404R-Fc), this article is aimed to generate an anti-VEGFR-2 human IgG1-like full length antibody (Mab-04). Firstly, the light chain (L-chain) and heavy chain (H-chain) were obtained by overlap PCR and then linked to eukaryotic expression vector pcDNA3.1, separately. The recombinant plasmids (pcDNA3.1-L-chain and pcDNA3.1-H-chain) were then co-transfected into CHO-k cells using liposome transient transfection. Subsequently, Mab-04 antibody was expressed and purified by Protein A affinity chromatography. Western blotting was applied to identify the expression of Mab-04 and its affinity was detected by ELISA assay. DNA sequencing revealed the successful construction of recombinant plasmids and Western blotting assay proved the successful expression of full-length antibody (1 microg x mL(-1)). Finally, ELISA assay illustrated that the binding of the antibody to its antigen was in a concentration-dependent manner (IC50: 50 nmol x L(-1)). These outcomes above indicated that Mab-04 was successfully expressed and assembled, which laid the foundation for further preparation and antineoplastic activity study.


Assuntos
Animais , Anticorpos Monoclonais Humanizados , Células CHO , Cricetulus , Vetores Genéticos , Fragmentos Fc das Imunoglobulinas , Genética , Imunoglobulina G , Genética , Alergia e Imunologia , Plasmídeos , Proteínas Recombinantes de Fusão , Genética , Anticorpos de Cadeia Única , Genética , Transfecção , Receptor 2 de Fatores de Crescimento do Endotélio Vascular , Genética , Alergia e Imunologia
2.
Acta Pharmaceutica Sinica ; (12): 1269-1274, 2012.
Artigo em Chinês | WPRIM | ID: wpr-274666

RESUMO

With the development of therapeutic monoclonal antibodies, the therapeutic antibodies have increasingly dominated the global pharmacy market in recent years, which are concentrated on the treatment of carcinoma, transplant rejection, auto-immune diseases etc. Meanwhile, the therapeutic antibodies could be categorized on the humanized proportion into several different types, such as murine-derived antibody, chimeric antibody, humanized antibody and human antibody. Herein, we focused both on antibody research hot spots and humanized anti-tumor antibody drugs. Moreover, in accordance with the classical examples of humanized anti-tumor antibody drugs approved by relevant authorities worldwide, we explained the research status and situation from both the humanized technologies and production of humanized antibodies. Additionally, it seemingly rational and reasonable to demonstrate the trend of further humanized anti-tumor antibody drugs in the prospect of the present situation either domestic or overseas.


Assuntos
Animais , Humanos , Anticorpos Monoclonais Humanizados , Alergia e Imunologia , Usos Terapêuticos , Antineoplásicos , Alergia e Imunologia , Usos Terapêuticos , Neoplasias , Terapêutica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA